Interventional, monocentric, national, single-arm, uncontrolled, open, prospective phase IV study. Since this study is not powered for confirmative testing, analysis is done by descriptive statistics Eligible AK patients receive Tirbanibulin on sun-damaged areas of the face for five days, according to the SmPC. Diagnosis and monitoring of treatment effects are supported by UV imaging using Canfield VISIA®. Safety and efficacy are assessed at end of treatment visit (EoT, approximately 3 days after the last dose, i.e, day 8 ± 2) and at a follow-up visit (FuV) 57 ± 7 d after the start of the treatment. UV images (Canfield VISIA®) will be taken at baseline, EoT and FuV, accompanied by conventional dermatological assessment according to clinical routine.

Inclusion Criteria:

• Informed consent
• Diagnosed with sun-damaged skin on the face and AK in the treatment area
• Willing and able to comply with all study procedures
• Use of medically acceptable contraception in males or females of child-bearing potential
• 51 -100 years of age
• Negative pregnancy test at baseline in females of childbearing potential

Exclusion Criteria:

• Allergy or intolerance towards the active ingredient or any of the constituents of the IMP
• Any contraindication for the IMP, according to the most recent version of the SmPC
• Open lesions of any kind on the face
• Concomitant cutaneous malignancy in treatment area, including but not restricted to squamous skin cancer
• Immune deficiency
• Participation in another clinical trial during the last six months
• Pregnancy or lactation